5 FDA decisions to watch in the fourth quarter October 2, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on 5 FDA decisions to watch in the fourth quarter The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer. Click here to view original post